Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association

Jacobson, 2015, National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1 - full report, J Clin Lipidol, 9, 129, 10.1016/j.jacl.2015.02.003 Jacobson, 2015, National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2, J Clin Lipidol, 9, S1, 10.1016/j.jacl.2015.09.002 Davidson, 2011, Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists, J Clin Lipidol, 5, 338, 10.1016/j.jacl.2011.07.005 Halperin, 2016, Further evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, 67, 1572, 10.1016/j.jacc.2015.09.001 Grundy, 2019, 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, Circulation, 139, e1082 Nordestgaard, 2010, Lipoprotein(a) as a cardiovascular risk factor: current status, Eur Heart J, 31, 2844, 10.1093/eurheartj/ehq386 Kronenberg, 2013, Lipoprotein(a): resurrected by genetics, J Intern Med, 273, 6, 10.1111/j.1365-2796.2012.02592.x Tsimikas, 2017, A test in context: Lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies, J Am Coll Cardiol, 69, 692, 10.1016/j.jacc.2016.11.042 Nordestgaard, 2016, Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology, J Lipid Res, 57, 1953, 10.1194/jlr.R071233 Boffa, 2016, Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?, J Lipid Res, 57, 745, 10.1194/jlr.R060582 Brown, 1987, Plasma lipoproteins: teaching old dogmas new tricks, Nature, 330, 113, 10.1038/330113a0 Ishikawa, 2013, Inverse association between serum lipoprotein(a) and cerebral hemorrhage in the Japanese population, Thromb Res, 131, e54, 10.1016/j.thromres.2012.11.032 Langsted, 2017, High lipoprotein(a) and low risk of major bleeding in brain and airways in the general population: a Mendelian randomization study, Clin Chem, 63, 1714, 10.1373/clinchem.2017.276931 Kinpara, 2011, Lipoprotein(a)-cholesterol: a significant component of serum cholesterol, Clin Chim Acta, 412, 1783, 10.1016/j.cca.2011.05.036 Zheng, 2019, Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis, J Am Coll Cardiol, 73, 2150, 10.1016/j.jacc.2019.01.070 Boffa, 2019, Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease, Nat Rev Cardiol, 16, 305, 10.1038/s41569-018-0153-2 Kamstrup, 2017, Oxidized phospholipids and risk of calcific aortic valve disease: The Copenhagen General Population Study, Arterioscler Thromb Vasc Biol, 37, 1570, 10.1161/ATVBAHA.116.308761 Yeang, 2016, Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis, Curr Opin Cardiol, 31, 440, 10.1097/HCO.0000000000000300 Craig, 1998, Lipoprotein(a) as a risk factor for ischemic heart disease: meta-analysis of prospective studies, Clin Chem, 44, 2301, 10.1093/clinchem/44.11.2301 Danesh, 2000, Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies, Circulation, 102, 1082, 10.1161/01.CIR.102.10.1082 Collaboration, 2009, Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality, JAMA, 302, 412, 10.1001/jama.2009.1063 Nave, 2015, Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis, Atherosclerosis, 242, 496, 10.1016/j.atherosclerosis.2015.08.021 Erqou, 2010, Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants, J Am Coll Cardiol, 55, 2160, 10.1016/j.jacc.2009.10.080 Sultan, 2014, Review of lipid and lipoprotein(a) abnormalities in childhood arterial ischemic stroke, Int J Stroke, 9, 79, 10.1111/ijs.12136 Paré, 2019, Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups, Circulation, 139, 1472, 10.1161/CIRCULATIONAHA.118.034311 Kamstrup, 2008, Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study, Circulation, 117, 176, 10.1161/CIRCULATIONAHA.107.715698 Kamstrup, 2009, Genetically elevated lipoprotein(a) and increased risk of myocardial infarction, JAMA, 301, 2331, 10.1001/jama.2009.801 Kamstrup, 2014, Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population, J Am Coll Cardiol, 63, 470, 10.1016/j.jacc.2013.09.038 Kamstrup, 2012, Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis, Arterioscler Thromb Vasc Biol, 32, 1732, 10.1161/ATVBAHA.112.248765 Kamstrup, 2016, Elevated Lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population, JACC Heart Fail, 4, 78, 10.1016/j.jchf.2015.08.006 Langsted, 2019, High lipoprotein(a) and high risk of mortality, Eur Heart J, 40, 2760, 10.1093/eurheartj/ehy902 Langsted, 2019, Elevated lipoprotein(a) and risk of ischemic stroke, J Am Coll Cardiol, 74, 54, 10.1016/j.jacc.2019.03.524 Steffen, 2018, Lp(a) [Lipoprotein(a)]-related risk of heart failure is evident in whites but not in other racial/ethnic groups, Arterioscler Thromb Vasc Biol, 38, 2498, 10.1161/ATVBAHA.118.311220 Smith, 2003, Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?, Int J Epidemiol, 32, 1, 10.1093/ije/dyg070 Davey Smith, 2005, Genetic epidemiology and public health: hope, hype, and future prospects, Lancet, 366, 1484, 10.1016/S0140-6736(05)67601-5 Benn, 2018, From genome-wide association studies to Mendelian randomization: novel opportunities for understanding cardiovascular disease causality, pathogenesis, prevention, and treatment, Cardiovasc Res, 114, 1192 Burgess, 2018, Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis, JAMA Cardiol, 3, 619, 10.1001/jamacardio.2018.1470 Lamina, 2019, Lp(a)-GWAS-Consortium. Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a Mendelian randomization analysis, JAMA Cardiol, 4, 575, 10.1001/jamacardio.2019.1041 Arsenault, 2014, Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort, Circ Cardiovasc Genet, 7, 304, 10.1161/CIRCGENETICS.113.000400 Clarke, 2009, Genetic variants associated with Lp(a) lipoprotein level and coronary disease, N Engl J Med, 361, 2518, 10.1056/NEJMoa0902604 Trégouët, 2009, Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease, Nat Genet, 41, 283, 10.1038/ng.314 Schunkert, 2011, Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease, Nat Genet, 43, 333, 10.1038/ng.784 Thanassoulis, 2013, Genetic associations with valvular calcification and aortic stenosis, N Engl J Med, 368, 503, 10.1056/NEJMoa1109034 Helgadottir, 2018, Genome-wide analysis yields new loci associating with aortic valve stenosis, Nat Commun, 9, 987, 10.1038/s41467-018-03252-6 Utermann, 2001, Lipoprotein(a), 2753 Marcovina, 2016, Lipoprotein (a) measurements for clinical application, J Lipid Res, 57, 526, 10.1194/jlr.R061648 Tsimikas, 2018, NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis, J Am Coll Cardiol, 71, 177, 10.1016/j.jacc.2017.11.014 Marcovina, 2000, Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a), Clin Chem, 46, 1956, 10.1093/clinchem/46.12.1956 Marcovina, 2003, Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions, Clin Chem, 49, 1785, 10.1373/clinchem.2003.023689 Marcovina, 1995, Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a), Clin Chem, 41, 246, 10.1093/clinchem/41.2.246 Enkhmaa, 2016, Lipoprotein (a) : impact by ethnicity and environmental and medical conditions, J Lipid Res, 57, 1111, 10.1194/jlr.R051904 Guan, 2015, Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis, Arterioscler Thromb Vasc Biol, 35, 996, 10.1161/ATVBAHA.114.304785 Virani, 2012, Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study, Circulation, 125, 241, 10.1161/CIRCULATIONAHA.111.045120 Willeit, 2018, Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials, Lancet, 392, 1311, 10.1016/S0140-6736(18)31652-0 O'Donoghue, 2014, Lipoprotein(a) for risk assessment in patients with established coronary artery disease, J Am Coll Cardiol, 63, 520, 10.1016/j.jacc.2013.09.042 Cantin, 1998, Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study, J Am Coll Cardiol, 31, 519, 10.1016/S0735-1097(97)00528-7 Khera, 2014, Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), Circulation, 129, 635, 10.1161/CIRCULATIONAHA.113.004406 Albers, 2013, Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes), J Am Coll Cardiol, 62, 1575, 10.1016/j.jacc.2013.06.051 Gaudet, 2017, Effect of alirocumab on lipoprotein(a) over ≥1.5 years (from the phase 3 ODYSSEY program), Am J Cardiol, 119, 40, 10.1016/j.amjcard.2016.09.010 Raal, 2014, Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials, J Am Coll Cardiol, 63, 1278, 10.1016/j.jacc.2014.01.006 Catapano, 2016, 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias, Eur Heart J, 37, 2999, 10.1093/eurheartj/ehw272 Anderson, 2016, 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult, Can J Cardiol, 32, 1263, 10.1016/j.cjca.2016.07.510 Langsted, 2016, High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study, Lancet Diabetes Endocrinol, 4, 577, 10.1016/S2213-8587(16)30042-0 Utermann, 1989, Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis, Proc Natl Acad Sci U S A, 86, 4171, 10.1073/pnas.86.11.4171 Willeit, 2014, Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study, J Am Coll Cardiol, 64, 851, 10.1016/j.jacc.2014.03.061 Ellis, 2019, Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia, J Am Coll Cardiol, 73, 1029, 10.1016/j.jacc.2018.12.037 Cook, 2018, Lipoprotein(a) and cardiovascular risk prediction among women, J Am Coll Cardiol, 72, 287, 10.1016/j.jacc.2018.04.060 Verbeek, 2018, Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting, Eur Heart J, 39, 2589, 10.1093/eurheartj/ehy334 Min, 1997, Relation between lipoprotein(a) concentrations in patients with acute-phase response and risk analysis for coronary heart disease, Clin Chem, 43, 1891, 10.1093/clinchem/43.10.1891 Suk Danik, 2008, Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events, J Am Coll Cardiol, 52, 124, 10.1016/j.jacc.2008.04.009 Hulley, 1998, Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group, JAMA, 280, 605, 10.1001/jama.280.7.605 Shlipak, 2000, Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause, JAMA, 283, 1845, 10.1001/jama.283.14.1845 Sahebkar, 2016, Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials, Metabolism, 65, 1664, 10.1016/j.metabol.2016.08.007 Landray, 2014, Effects of extended-release niacin with laropiprant in high-risk patients, N Engl J Med, 371, 203, 10.1056/NEJMoa1300955 Anderson, 2014, Safety profile of extended-release niacin in the AIM-HIGH trial, N Engl J Med, 371, 288, 10.1056/NEJMc1311039 Parish, 2018, Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE Study, Circ Genom Precis Med, 11, 10.1161/CIRCGEN.117.001696 O'Donoghue, 2019, Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk, Circulation, 139, 1483, 10.1161/CIRCULATIONAHA.118.037184 Bittner, 2018, Lp(a) and cardiovascular outcomes: an analysis from the ODYSSEY OUTCOMES Trial, Atherosclerosis Supplements, 32, 24, 10.1016/j.atherosclerosissup.2018.04.072 Bittner, 2019, Lipoprotein (a) lowering by alirocumab contributes to event reduction independent of low-density lipoprotein cholesterol in the ODYSSEY OUTCOMES trial Vuorio, 2017, Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a), Eur Heart J, 38, 3555, 10.1093/eurheartj/ehx546 Arai, 2012, Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia, J Lipid Res, 53, 1670, 10.1194/jlr.P027235 Moriarty, 2015, Lipoprotein apheresis, Cardiol Clin, 33, 197, 10.1016/j.ccl.2015.02.002 Schettler, 2017, The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on, Clin Res Cardiol Suppl, 12, 44, 10.1007/s11789-017-0089-9 Jaeger, 2009, Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events, Nat Clin Pract Cardiovasc Med, 6, 229 Rosada, 2014, Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?, Artif Organs, 38, 135, 10.1111/aor.12135 Roeseler, 2016, Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization, Arterioscler Thromb Vasc Biol, 36, 2019, 10.1161/ATVBAHA.116.307983 Khan, 2017, Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial, Eur Heart J, 38, 1561, 10.1093/eurheartj/ehx178 Capoulade, 2015, Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis, J Am Coll Cardiol, 66, 1236, 10.1016/j.jacc.2015.07.020 Hoff, 1988, Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients, Circulation, 77, 1238, 10.1161/01.CIR.77.6.1238 Wei, 2018, LPA variants are associated with residual cardiovascular risk in patients receiving statins, Circulation, 138, 1839, 10.1161/CIRCULATIONAHA.117.031356 Smolders, 2007, Lipoprotein (a) and stroke: a meta-analysis of observational studies, Stroke, 38, 1959, 10.1161/STROKEAHA.106.480657 Rallidis, 2018, High levels of lipoprotein (a) and premature acute coronary syndrome, Atherosclerosis, 269, 29, 10.1016/j.atherosclerosis.2017.12.011 Kotani, 2016, Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases - Some answers and still many questions, Crit Rev Clin Lab Sci, 53, 370, 10.1080/10408363.2016.1188055 Chen, 2018, Association of LPA variants with aortic stenosis: a large-scale study using diagnostic and procedural codes from electronic health records, JAMA Cardiol, 3, 18, 10.1001/jamacardio.2017.4266 Postmus, 2014, Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins, Nat Commun, 5, 5068, 10.1038/ncomms6068 Deshmukh, 2012, Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a), J Lipid Res, 53, 1000, 10.1194/jlr.P021113 Genest, 1992, Familial lipoprotein disorders in patients with premature coronary artery disease, Circulation, 85, 2025, 10.1161/01.CIR.85.6.2025 CARDIoGRAMplusC4D Consortium, 2013, Large-scale association analysis identifies new risk loci for coronary artery disease, Nat Genet, 45, 25, 10.1038/ng.2480 Ellis, 2016, Familial combined hyperlipidemia and hyperlipoprotein(a) as phenotypic mimics of familial hypercholesterolemia: Frequencies, associations and predictions, J Clin Lipidol, 10, 1329, 10.1016/j.jacl.2016.08.011 Pérez de Isla, 2017, Predicting cardiovascular events in familial hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study), Circulation, 135, 2133, 10.1161/CIRCULATIONAHA.116.024541 Vongpromek, 2015, Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia, J Intern Med, 278, 166, 10.1111/joim.12335 Nestel, 2013, Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease, Arterioscler Thromb Vasc Biol, 33, 2902, 10.1161/ATVBAHA.113.302479 Marcovina, 2018, JCL roundtable-Lipoprotein(a): The emerging risk factor, J Clin Lipidol, 12, 1335, 10.1016/j.jacl.2018.11.003 Kenet, 2010, Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies, Circulation, 121, 1838, 10.1161/CIRCULATIONAHA.109.913673 Lapinleimu, 2015, High lipoprotein(a) concentrations are associated with impaired endothelial function in children, J Pediatr, 166, 947, 10.1016/j.jpeds.2014.12.051 Qayum, 2018, Lipoprotein (a): examination of cardiovascular risk in a pediatric referral population, Pediatr Cardiol, 39, 1540, 10.1007/s00246-018-1927-3 Nowak-Göttl, 1999, Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood, Blood, 94, 3678, 10.1182/blood.V94.11.3678 Goldenberg, 2013, Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children, Haematologica, 98, 802, 10.3324/haematol.2012.073833 von Depka, 2000, Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism, Blood, 96, 3364, 10.1182/blood.V96.10.3364 Sultan, 2018, Dyslipidemia in children with arterial ischemic stroke: prevalence and risk factors, Pediatr Neurol, 78, 46, 10.1016/j.pediatrneurol.2017.09.019 2011, Pediatrics, 128, S213 Zawacki, 2018, In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members, J Clin Lipidol, 12, 1445, 10.1016/j.jacl.2018.07.014 Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med, 372, 2387, 10.1056/NEJMoa1410489 Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5 Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N Engl J Med, 376, 1713, 10.1056/NEJMoa1615664 Schwartz, 2018, Alirocumab and cardiovascular outcomes after acute coronary syndrome, N Engl J Med, 379, 2097, 10.1056/NEJMoa1801174